Effects of the Vasopressin V2 Receptor Antagonist, Tolvaptan, on the Long-term Progression of Left Ventricular Dilatation in Patients with Heart Failure

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2005.10.008 ◽

2005 ◽

Vol 11 (9) ◽

pp. 720

Author(s):

James E. Udelson

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Left Ventricular ◽

Ventricular Dilatation ◽

Left Ventricular Dilatation ◽

Patients With Heart Failure ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

V2 Receptor Antagonist

Download Full-text

Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats

International Journal of Cardiology ◽

10.1016/j.ijcard.2005.05.009 ◽

2006 ◽

Vol 108 (2) ◽

pp. 231-236 ◽

Author(s):

Masayuki Takeuchi ◽

Jong-Dae Lee ◽

Hiromasa Shimizu ◽

Takanori Ueda

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Oral Treatment ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

V2 Receptor Antagonist

Download Full-text

Tolvaptan, an Oral Vasopressin V2 Receptor Antagonist for Heart Failure?

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2007.10.006 ◽

2007 ◽

Vol 50 (6) ◽

pp. 904-907

Author(s):

Arthur Greenberg

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

V2 Receptor Antagonist

Download Full-text

Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure

Journal of Cardiology ◽

10.1016/j.jjcc.2020.05.012 ◽

2020 ◽

Vol 76 (5) ◽

pp. 499-505

Author(s):

Koji Takagi ◽

Naoki Sato ◽

Shiro Ishihara ◽

Hayano Iha ◽

Noriyuki Kobayashi ◽

...

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Pharmacological Property ◽

Combined Therapy ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

V2 Receptor Antagonist

Download Full-text

Effects of Oral Tolvaptan on Left Ventricular Dilatation and Function in Patients with Heart Failure and Left Ventricular Systolic Dysfunction

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2005.08.091 ◽

2005 ◽

Vol 11 (9) ◽

pp. S263

Author(s):

Cesare Orlandi ◽

James Udelson ◽

Christopher Zimmer ◽

John Ouyang ◽

Yoshitaka Yamamura ◽

...

Keyword(s):

Heart Failure ◽

Left Ventricular Systolic Dysfunction ◽

Systolic Dysfunction ◽

Left Ventricular ◽

Ventricular Dilatation ◽

Ventricular Systolic Dysfunction ◽

Left Ventricular Dilatation ◽

Patients With Heart Failure ◽

Download Full-text

Effect of Long-Term Treatment with Selective Vasopressin V1 and V2 Receptor Antagonist on the Development of Heart Failure in Rats

Journal of Cardiovascular Pharmacology ◽

10.1097/00005344-199602000-00015 ◽

1996 ◽

Vol 27 (2) ◽

pp. 275-282 ◽

Author(s):

Toshio Nishikimi ◽

Yuhei Kawano ◽

Yoshihiko Saito ◽

Hiroaki Matsuoka

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Term Treatment ◽

Long Term Treatment ◽

V2 Receptor ◽

V2 Receptor Antagonist

Download Full-text

The vasopressin V2-receptor antagonist, tolvaptan, can not only induce aquaresis but also enhance natriuresis in heart failure patients refractory to loop diuretics

European Heart Journal ◽

10.1093/eurheartj/eht309.p3338 ◽

2013 ◽

Vol 34 (suppl 1) ◽

pp. P3338-P3338 ◽

Author(s):

Y. Ikeda ◽

T. Inomata ◽

Y. Iida ◽

T. Nabeta ◽

M. Iwamoto ◽

...

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Loop Diuretics ◽

Heart Failure Patients ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

V2 Receptor Antagonist

Download Full-text

102 EFFECTS OF SATAVAPTAN, AN ORAL VASOPRESSIN V2 RECEPTOR ANTAGONIST, ON MANAGEMENT OF ASCITES AND MORBIDITY IN LIVER CIRRHOSIS IN A LONG-TERM, PLACEBO-CONTROLLED STUDY

Journal of Hepatology ◽

10.1016/s0168-8278(09)60104-5 ◽

2009 ◽

Vol 50 ◽

pp. S42-S43 ◽

Author(s):

F. Wong ◽

M. Bernardi ◽

Y. Horsmans ◽

Z. Cabrijan ◽

H. Watson ◽

...

Keyword(s):

Liver Cirrhosis ◽

Receptor Antagonist ◽

Controlled Study ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

V2 Receptor Antagonist

Download Full-text

Aquaretic and hormonal effects of a vasopressin V2 receptor antagonist after acute and long-term treatment in rats

European Journal of Pharmacology ◽

10.1016/s0014-2999(00)00088-1 ◽

2000 ◽

Vol 394 (1) ◽

pp. 131-138 ◽

Author(s):

Colette Lacour ◽

Gérard Galindo ◽

Françoise Canals ◽

Danielle Segondy ◽

Catherine Cazaubon ◽

...

Keyword(s):

Receptor Antagonist ◽

Term Treatment ◽

Hormonal Effects ◽

Vasopressin V2 Receptor ◽

Long Term Treatment ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

V2 Receptor Antagonist

Download Full-text

Renoprotective Effect of Vasopressin V2 Receptor Antagonist Tolvaptan in Dahl Rats With End-Stage Heart Failure

International Heart Journal ◽

10.1536/ihj.54.98 ◽

2013 ◽

Vol 54 (2) ◽

pp. 98-106 ◽

Author(s):

Mayuko Ishikawa ◽

Naohiko Kobayashi ◽

Fumihiro Sugiyama ◽

Sho Onoda ◽

Toshihiko Ishimitsu

Keyword(s):

Heart Failure ◽

Receptor Antagonist ◽

Renoprotective Effect ◽

Vasopressin V2 Receptor ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

End Stage Heart Failure ◽

End Stage ◽

V2 Receptor Antagonist

Download Full-text

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2 -receptor antagonist: the DILIPO study

European Journal of Heart Failure ◽

10.1093/eurjhf/hfq226 ◽

2011 ◽

Vol 13 (3) ◽

pp. 327-336 ◽

Author(s):

Doron Aronson ◽

Joseph G. Verbalis ◽

Matthias Mueller ◽

Henry Krum ◽

Keyword(s):

Receptor Antagonist ◽

Arginine Vasopressin ◽

Term Treatment ◽

Long Term Treatment ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

Short And Long Term ◽

Dilutional Hyponatraemia ◽

V2 Receptor Antagonist

Download Full-text